BP-1-102

BP-1-102 (CAS No.: 1334493-07-0) is an orally bioavailable small-molecule inhibitor of the transcription factor STAT3, widely utilized in cancer biology and signal transduction research. This compound directly binds STAT3 with submicromolar affinity and disrupts its interaction with phosphotyrosine-containing peptides, thereby preventing STAT3 activation and downstream transcriptional activity within the low micromolar range. By selectively targeting STAT3-dependent signaling pathways, BP-1-102 inhibits the proliferation, migration, survival, and invasive capacity of multiple tumor cell lines while exhibiting reduced effects in STAT3-independent models, highlighting its pathway specificity. Mechanistically, inhibition of aberrant STAT3 activity by BP-1-102 leads to downregulation of key oncogenic and pro-survival genes, including c-Myc, Bcl-xL, cyclin D1, survivin, and VEGF, which are critical mediators of tumor progression and angiogenesis. In vitro studies demonstrate decreased viability and proliferation in STAT3-driven cancer cells at micromolar concentrations, while in vivo investigations in xenograft models show suppression of tumor growth and associated gene expression. BP-1-102 is therefore a valuable pharmacological tool for probing STAT3-mediated oncogenic signaling and for evaluating therapeutic strategies targeting STAT3 in oncology, with experimental concentrations or dosing regimens typically optimized according to specific cellular or animal model systems.